glp 1 and parkinson's disease Repurposing GLP-1 Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine What do you do with

34,64 However, the coexistence of GIP and GLP-1 in patients with T2D produces glucagon concentrations akin to control conditions

So, what options are there for folks who dont necessarily want to taper off of their GLP-1

recommended 3 servings)

The 2024 semaglutide phase 2 RCT and the Weill Cornell cohort data are the most rigorous current evidence showing bone loss - but reasonable endocrinologists interpret even those findings with appropriate uncertainty about generalizability

For everyone else, current evidence indicates no meaningful increase in thyroid cancer risk with GLP-1RAs

doi: 10.1089/dia.2014.0188 9 BettgeKKahleMAbd El AzizMSMeierJJNauckMA